Navigation Links
Tokai Pharmaceuticals' galeterone well-tolerated in patients with advanced prostate cancer
Date:3/31/2012

CAMBRIDGE, Mass. and CHICAGO, Ill. -- Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study. The data will be presented in an oral presentation titled, "ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy nave patients with castration-resistant prostate cancer (CRPC)," abstract number CT-07, on Tuesday, April 3, 2012 at 3:05 p.m. (CDT) at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago.

CRPC is an advanced, difficult-to-treat form of prostate cancer that occurs when the disease progresses despite the use of anti-hormonal therapies. Galeterone is a small molecule, oral drug for the treatment of CRPC that disrupts the growth and survival of prostate cancer cells via a novel and proprietary triple mechanism of action.

"Because currently available therapeutic options to treat castration-resistant prostate cancer are limited, often poorly-tolerated and may fail because of resistance, patients are in urgent need of new safe and effective treatments," said Mary-Ellen Taplin, M.D., associate professor of medicine, director of genitourinary clinical research, Dana-Farber Cancer Institute, Harvard Medical School and co-lead researcher in the study. "These Phase 1 galeterone data, demonstrating minimal toxicities, improved PSA response and a reduction in tumor size, are exciting for those of us in the medical community treating this life-threatening cancer. I look forward to following the further development of galeterone as a promising approach in the treatment of prostate cancer."

The ARMOR1 study was led by co-principal investigators Dr. Taplin and Bruce Montgomery, M.D., associate professor of medical oncolo
'/>"/>

Contact: Caton Lovett
caton@purecommunicationsinc.com
910-232-7166
Pure Communications Inc.
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
2. 2012 Biotechnology and Pharmaceuticals: Forthcoming Conferences and Exhibitions
3. Study finds an increase of children accidentally poisoned with pharmaceuticals
4. Study Shows Sutro Biopharmas Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals
5. PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. Enter into a Licensing and Collaboration Agreement on PEP02 (MM-398), Nanoliposomal Irinotecan
6. Environmental risk assessment of pharmaceuticals inadequate
7. Brown licenses potential muscular dystrophy treatment to Tivorsan Pharmaceuticals
8. CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
9. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
10. NIH awards $8.5 million for research on pharmaceuticals for children
11. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... DUBLIN , Mar. 19, 2015 Research and Markets ... the "Iris Biometrics - Global Strategic Business Report" ... worldwide markets for Iris Biometrics in US$ Thousands. The report ... , Japan , Europe ... East , and Latin America . ...
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... study, published in the March issue of Human Nature ... difference in their subjective ratings of photos of men when ... who did not have sexual partners spent more time evaluating ... No such difference was found between men who had sexual ...
... , This release is available in <A ... spread and devastating natural disaster across the globe. It ... annual damage of about 1.5 billion. The figure is ... few years (Association of British Insurers). Floods that took ...
... of environmental change? Evolvequickly. A new article in The ... new habitats developed new and advantageous traits in just a ... to look at adaptation and survival in a wild population. ... the University of California, Riverside studied 200 guppies that had ...
Cached Biology News:Single women gaze longer 2Next-generation software system for flood warning and risk analysis to be developed 2When evolution is not so slow and gradual 2
(Date:3/27/2015)... March 27, 2015 WuXi PharmaTech (Cayman) ... R&D capability and technology platform company serving the ... today that an Investigational New Drug (IND) application ... rheumatoid arthritis has been accepted for review by ... In September 2012, MedImmune, the global ...
(Date:3/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... including the appointment of auditors, its annual and special ... "Meeting") was adjourned, as previously disclosed on March 25, ... Toronto time). The date of the ... The Meeting will reconvene at the offices of the ...
(Date:3/26/2015)... BOSTON , March 26, 2015 /PRNewswire/ ... ), a global clinical research organization ... signed a definitive agreement to acquire all ... India ("QSI"), a leading provider of specialized ... refers to the collection, detection, assessment, monitoring, ...
(Date:3/25/2015)... pharmaceutical market is one of the most ... its absolute size, plus a growing economy and increasing ... Business Monitor International. The Russian market is set to ... market, with growth estimates around 10-15% annually reaching an ... About Green Cross Green Cross provides ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3SQI Diagnostics Inc. Announces Adjournment of Meeting 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... Aug. 20 Advanced Cell,Technology, Inc. (OTC Bulletin ... conditions, it plans to privately offer up to ... timing of the,closing of the offering will be ... are expected to be used to fund working ...
... CEO Mark McDade to resign for personal reasons ... BioPharma, Inc.,(PDL) (Nasdaq: PDLI ) today announced ... executive officer (CEO), Mark McDade,found no credible evidence ... by McDade to corroborate the various allegations,investigated. The ...
... Supplier Presents Today at Small Cap Financial ... ... ), a leading provider of nitinol and polymer components to the,medical device ... for the fourth fiscal,quarter ended June 30, 2007, an increase of over ...
Cached Biology Technology:Advanced Cell Technology Announces Proposed Financing 2Advanced Cell Technology Announces Proposed Financing 3PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 3PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 4Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue 2Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue 3Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue 4
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
... N-(2-Naphthoyl)-Val-phenylalaninal 2-Naphthoyl-VF-CHO White lyophilized ... GAS. A cell-permeable, reversible inhibitor of γ-secretase. ... (ED 50 = 2.6 μM) ... = 2.7 μM) in HEK293 cells stably ...
...
Biology Products: